Viewpoint Molecular Targeting's Grant

Viewpoint Molecular Targeting raised a round of funding on August 27, 2015. Investors include National Cancer Institute.

Viewpoint Molecular Targeting develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. Its novel image-guided therapies enable a personalized a…

Articles about Viewpoint Molecular Targeting's Grant: